6. Harada K, Kawaguchi S, Supriatno , Onoue T, Yoshida H, Sato M: Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells. Oral Oncol 2004, 40:713–719.PubMedCrossRef 7. Shimosato Y, Oboshii S, Baba K: Histological evaluation of effects of radiotherapy and chemotherapy for carcinomas. Jpn J Clin Oncol 1971, 1:19–35. 8. Kaplan EL, Meier P: Nonparametric estimation from incomplete Rapamycin nmr observations. J Am Stat Assoc 1958, 53:457–481.CrossRef 9. Giralt JL, Gonzalez J, del Campo JM, Maldonado J, Sanz X, Pamias J, et al.: Preoperative

induction chemotherapy followed by concurrent chemoradiotherapy in advanced carcinoma of the oral cavity and oropharynx. Cancer 2000, 89:939–945.PubMedCrossRef 10. Adelstein DJ, Saxton JP, Rybicki LA, Esclamado RM, Wood BG, Strome M, et al.: Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J Clin Oncol 2006, 24:1064–1071.PubMedCrossRef 11. Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, et al.: Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol 2006, 24:4163–4169.PubMedCrossRef 12. Tsukuda

M, Kida A, Fujii M, Kono N, Yoshihara T, Hasegawa Y, et al.: Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer. Br J Cancer 2005, 93:884–889.PubMedCrossRef Selleck VX 809 13. Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B: S-1 cooperative study group (Head and Neck Cancer Working Group): Late phase II study of S-1 in patients with advanced head and neck

cancer. Gan To Kagaku Ryoho 2001, 28:1381–1390.PubMed 14. Tsukuda M, Ishitoya J, Mikami Y, Matsuda H, Horiuchi C, Taguchi T, et al.: Analysis of triclocarban feasibility and toxicity of concurrent chemoradiotherapy with S-1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity. Cancer Chemother Pharmacol 2009, 64:945–952.PubMedCrossRef 15. Mandenhall WM: Mandibular osteoradionecrosis. JClin Oncol 2004, 22:4867–4868.CrossRef 16. Glanzmann C, Gratz KW: Radionecrosis of the mandibula: a retrospective analysis of the incidence and risk factors. Radiother Oncol 1995, 36:94–100.PubMedCrossRef Authors’ contributions HH carried out clinical data collection, data review, participated in study design. KO was the principle investigation of the study and participated in all aspects of this work. All authors read and approved the final manuscript.”
“Background Gastric cancer is the second cancer cause of death in the world, although its incidence has declined in Western countries. Despite advances in its molecular characterization, to date, the only effective treatment is surgery with curative intent and the median 5-year survival is 25% [1].